Find the lastest updates or news with any bio tech companies in Korea and provide a summary.
Samsung Biologics posted record Q2 2026 revenue of 1.32 trillion won, while Korean biotech companies are expanding global exports through biosimilars and CDMOs. South Korea is also partnering with European nations on green biotech innovation and leveraging China's cost-effective clinical trial infrastructure for drug development.
Korean biotech companies are making significant strategic moves this week: Y-Biologics plans to launch global technology transfer talks after presenting November data, Seoul partners with Samsung Bioepis to nurture biotech startups, and Samsung Biologics pursues its largest-ever acquisition of Swiss peptide manufacturer PolyPeptide for $1.8 billion.
South Korea's biotech sector achieved a landmark milestone as Samsung Biologics announced a $1.8 billion acquisition of Switzerland's PolyPeptide Group—the largest M&A deal in Korean biotech history. Meanwhile, Korean biotech firms LigaChem Bio, ABL Bio, and Genome & Company are racing to develop next-generation antibody-drug conjugates (ADCs) to capture a share of big pharma's trillion-won cancer therapy investments. The Korea Biotechnology Industry Organization also strengthened regional ties by calling for closer bio supply chain cooperation with Taiwan.
South Korean biotech companies are accelerating clinical development and international partnerships this week, with Genexine advancing BioPROTAC cancer candidates and the government easing regulatory pathways for regenerative medicine. Luxembourg and Korea are establishing a clinical data-sharing collaboration to support AI-driven drug development.
South Korea is accelerating regulatory approval for regenerative medicine therapies and strengthening international biotech collaborations. Genexine targets global leadership in BioPROTAC protein degradation technology, while Luxembourg and Korea are building a clinical data-sharing gateway to fast-track AI-driven drug development.
SK Telecom and SK Biopharmaceuticals have achieved a major breakthrough using AI to accelerate drug discovery, cutting research time by 60% to identify cancer therapy compounds in just five months. Meanwhile, Celltrion has acquired novel antibody technology from Catholic University of Korea for autoimmune disease treatment, signaling continued momentum in Korea's biotech sector despite broader market volatility.
Samsung Bioepis has cracked proprietary subcutaneous injection technology to challenge patent-protected blockbuster drugs, while Savey Robotics unveils clean-sterile automation robots targeting bio-manufacturing efficiency gains of up to 70% labor cost reduction.
US biotech ventures are increasingly targeting KOSDAQ listings, with three companies securing major technology export deals with big pharma. Meanwhile, Korea launched the "K-Tech Pioneers" program to attract overseas talent in biotech and AI back home, as the sector grapples with a structural capital shortage amid the AI investment frenzy.
Korean biotech stocks face severe headwinds as capital flows shift toward AI chips and policy-driven sectors, with major companies like Yuhan recording significant divergence from price targets. The sector struggles with structural challenges including heavy licensing dependencies, while biopharmaceutical exports remain robust at record-setting levels. ABL Bio accelerates partnerships as the industry eyes major pharma deals despite market volatility.
South Korean biotech companies are gaining international recognition as innovation leaders, with Hanmi Pharmaceutical and SK Biopharmaceuticals named by Nature Reviews Drug Discovery for their R&D excellence. Meanwhile, platform technology companies like Alteogen are positioning Korean biotech for a potential rebound in the second half of 2026, though the sector continues to face capital constraints despite growing global opportunities.
Nature Reviews Drug Discovery has recognized Hanmi Pharmaceutical and SK Biopharmaceuticals as innovation leaders among emerging-market drugmakers, while SK Bioscience partners with the Gates Foundation on AI-driven vaccine development. Meanwhile, Korean biotech faces a persistent capital shortage despite gaining global attention at BIO 2026, forcing early-stage companies to sell technologies at discounted rates to major pharmaceutical firms.
South Korea's biotech sector secured a landmark $323 million investment from the government's chip fund backing LigaChem, while SK Bioscience announced accelerated growth driven by vaccine exports and CDMO expansion. Samsung Biologics released its 2026 ESG report highlighting sustainable operations as the Korean biotech ecosystem strengthens its global competitiveness.
Korea's biotech sector continues gaining momentum with LigaChem Biosciences securing 500 billion won ($323 million) from Korea's National Growth Fund, marking the first life sciences company to receive direct equity from the chip-focused vehicle. Meanwhile, Korean biotech companies are demonstrating world-class technology at major international conferences, though capital structure and investment innovation remain critical challenges for sustained global growth.
South Korea's biotech sector is gaining momentum with major government backing and international visibility. The National Growth Fund announced its first biotech investment, backing LigaChem Biosciences with $323 million, while the Korea Exchange actively courts global biotech IPOs at BIO International Convention 2026. Meanwhile, Celltrion showcases AI-driven drug discovery capabilities at the industry's flagship event.
Korean biotech companies are actively pursuing global partnerships and deals at BIO International Convention 2026 in San Diego, with SK biopharmaceuticals positioning itself as a bridge between Asian and Western markets. However, the sector faces intensifying competition from China's rapid advancement in drug development. Major Korean firms including Lotte Biologics and partnerships with AstraZeneca are on display this week.
Korean biotech companies are ramping up global expansion efforts at BIO 2026 in San Diego, with major dealmaking underway including a landmark $2.5 billion AI drug discovery partnership between SK Biopharmaceuticals and Insilico Medicine. Celltrion and other Korean firms are showcasing biosimilars, AI-driven research capabilities, and seeking international partnerships to accelerate their growth in competitive markets.
South Korean biotech companies are making significant strides on the global stage, with Seoul National University Hospital expanding K-Bio collaboration at BIO USA 2026, while Samyang Biopharm pursues platform licensing partnerships. Additionally, Matica Biotechnology has launched an integrated Korea IIT platform solution to accelerate advanced therapy development globally.
Korean biotech and pharmaceutical companies are making a major push at BIO USA 2026 (June 22-25 in San Diego), with Celltrion showcasing its AI-driven drug discovery platform and multiple firms seeking licensing deals, CDMO partnerships, and global expansion opportunities. Seoul National University Hospital is supporting five Korean biotech startups with dedicated booth presence at the convention.
South Korea's biotech sector continues strengthening with major international partnerships and government infrastructure investments. The Korea Disease Control and Prevention Agency launched a national supply of GMP-grade induced pluripotent stem cell lines on June 30, advancing cell therapy development, while Dongwon F&B invested 140 billion won in protein-based biotechnology manufacturing capacity.
Celltrion has selected four startups for its Seoul Bio Hub open innovation program, while South Korea's biotech sector is poised to benefit from eased US clinical trial approval processes that could accelerate development timelines for Korean firms like Samsung Biologics. Korea Life Science Week 2026 is underway, showcasing the nation's growing prominence in the life sciences sector.
Create custom signals on any topic. AI curates and delivers 24/7.
Create SignalPowered by
